|1.||Palecek, Jiri: 2 articles (06/2014 - 01/2014)|
|2.||Spicarova, Diana: 2 articles (06/2014 - 01/2014)|
|3.||Calixto, João B: 2 articles (01/2014 - 08/2006)|
|4.||Ferreira, Juliano: 2 articles (08/2013 - 08/2006)|
|5.||Ding, Zhe: 2 articles (04/2006 - 12/2005)|
|6.||Rawls, Scott M: 2 articles (04/2006 - 12/2005)|
|7.||Cowan, Alan: 2 articles (04/2006 - 12/2005)|
|8.||Shoji, Noriaki: 1 article (12/2015)|
|9.||Satoh-Kuriwada, Shizuko: 1 article (12/2015)|
|10.||Takeda, Mamoru: 1 article (12/2015)|
|1.||Wounds and Injuries (Trauma)
02/01/2007 - "This study examines these possibilities using rat models of compression trauma-induced SCI. Both SB366791, a specific vanilloid receptor antagonist, and CGRP (8-37), a CGRP receptor antagonist, significantly inhibited trauma-induced increases in spinal cord tissue 6-keto-PGF(1alpha) levels. "
02/01/2007 - "SB366791, CGRP (8-37) and indomethacin (IM) enhanced increases in spinal cord tissue TNF levels at 2h after trauma and exacerbated motor disturbances. "
|2.||Prostatic Neoplasms (Prostate Cancer)
12/01/2015 - "Following TNBS treatment, the successive administration of the transient receptor potential vanilloid 1 (TRPV1) antagonist SB366791 or neutralizing anti-Artn antibody completely inhibited the heat hyperalgesia. "
03/01/2015 - "Administration of the TRPV1 antagonist, SB366791, to the incised site produced a significant suppression of heat hyperalgesia in both the buccal mucosa and whisker pad skin, as well as mechanical allodynia in the whisker pad skin. "
01/01/2014 - "Local intradermal SB366791 treatment reduced thermal hyperalgesia and mechanical allodynia without affecting mechanical hyperalgesia. "
01/01/2014 - "A single intrathecal administration of SB366791 significantly reduced postincisional thermal hyperalgesia and also attenuated mechanical allodynia, while mechanical hyperalgesia remained unaffected. "
01/01/2013 - "AP18, administered in combination with a subeffective dose of SB366791, significantly suppressed the referred hyperalgesia. "
10/01/2014 - "Notably, intracerebral TRPV1 antagonism by SB 366791 significantly reduced chemical and inflammatory spontaneous abdominal nocifensive responses, as observed by reduced expressions of nociceptive facial grimacing, illustrating the affective component of pain. "
03/01/2015 - "The effect of TRPV4 antagonist RN1734 and TRPV1 antagonist SB366791 on bladder hyperactivity and pain induced by cystitis was assessed by cystometry and visceral pain behaviour tests, respectively. "
02/01/2009 - "Our findings showed that the combination of morphine and SB366791 has potent analgesic effects on bone cancer pain. "
02/01/2009 - "The analgesic effects of the combination of SB366791 and morphine on bone cancer pain were also examined. "
02/01/2009 - "The analgesic effects of intraperitoneal morphine and the analgesic effect of a TRPV1 antagonist, SB366791 [N-(3-methoxyphenyl)-4-chlorocinnamide], on bone cancer pain-related behaviours were examined. "
08/01/2013 - "Intraplantar or intrathecal administered Phα1β reduced both nocifensive behavior and mechanical hypersensitivity induced by capsaicin similarly to that observed with SB366791, a specific TRPV1 antagonist. "
06/01/2014 - "The intrathecal application of CCL2 induced thermal hyperalgesia and mechanical allodynia, while pretreatment with the TRPV1 receptor antagonist SB366791 diminished the thermal but not the mechanical hypersensitivity. "
01/01/2014 - "The CXCR2 antagonist, SB225002, the TRPV1 channel antagonist, SB366791 or their combination reduced the mechanical hypersensitivity of paw and abdominal area and nociceptive behaviour after cyclophosphamide. "
|3.||Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)
|4.||calcitonin gene-related peptide (8-37)
|6.||Morphine (MS Contin)
|7.||CB2 Cannabinoid Receptor
|9.||Neurokinin-1 Receptors (Neurokinin 1 Receptor)
|1.||Self Administration (Administration, Self)